Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report.

paythelady.612 shared this article with you from Inoreader Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report. Μέσω pubmed: "world j clin cases"... Related Articles Primary duodenal tuberculosis misdiagnosed as tumor by imaging examination: A case report. World J Clin Cases. 2020 Dec 26;8(24):6537-6545 Authors: Zhang Y, Shi XJ, Zhang XC, Zhao XJ, Li JX, Wang LH, Xie CE, Liu YY, Wang YL Abstract BACKGROUND: Primary duodenal tuberculosis is very rare. Due to a lack of specificity for its presenting symptoms, it is easily misdiagnosed clinically. Review of the few case reports and literature on the topic will help to improve the overall understanding of this disease and aid in differential diagnosis to improve patient outcome. CASE SUMMARY: A 71-year-old man with a 30-plus year history of bronchiectasis and bronchitis presented to the Gastroenterology Department of our hospital complaining of intermittent upper abdominal pain. Initial imaging examination revealed a duodenal space-occupying lesion; subsequent upper abdominal contrast-enhanced computed tomography indicated duodenal malignant tumor. Physical and laboratory examinations showed no obvious abnormalities. In order to confirm further the diagnosis, electronic endoscopy was performed and tissue biopsies were taken. Duodenal histopathology showed granuloma and necrosis. In-depth tuberculosis-related examination did not rule out tuberculosis, so we initiated treatment with anti-tuberculosis drugs. At 6 mo after the anti-tuberculosis drug course, there were no signs of new development of primary lesions by upper abdominal computed tomography, and no complications had manifested. CONCLUSION: This case emphasizes the importance of differential diagnosis for gastrointestinal diseases. Duodenal tuberculosis requires a systematic examination and physician awareness. PMID: 33392342 [PubMed] View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.